Kelun, Merck's lung cancer combo improves survival in late-stage China trial
- Posted on May 21, 2026
- By Bing News
- 0 Views
- 1 min read
Kelun, Merck's lung cancer combo improves survival in late-stage China trial
May 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's Keytruda improved survival rate in patients with advanced lung cancer, meeting the main goal of a late-stage study. The trial tested the drug, sacituzumab tirumotecan or sac-TMT, in combination with cancer therapy Keytruda as a first-line treatment for patients with
